A Study of CI-1012 in HIV-Infected Patients

Launched by PARKE-DAVIS · Aug 30, 2001

Keywords

ClinConnect Summary

Patients receive 2 weeks of oral CI-1012 therapy in this open-label study, with 8 patients entered at each dose level studied.

Gender

ALL

Eligibility criteria

• • Inclusion Criteria
• Patients must have:
• • Serologic evidence of infection with HIV-1.
• • CD4+ cell count \>= 200 cells/mm3.
• • HIV-1 RNA \>= 10,000 copies/ml.
• • Exclusion Criteria
• Co-existing Condition:
• Patients with the following conditions are excluded:
• • Viral, fungal, or bacterial infection requiring therapy other than topical medications.
• Concurrent Medication:
• Excluded:
• • Prophylactic systematic antibacterial, antifungal or antiviral agents.
• * Antiretroviral therapy. NOTE:
• • Patient must be willing to remain off antiretroviral therapy for 1 week after completing study medication.
• Prior Medication:
• Excluded:
• • Experimental therapy for \>= 4 weeks prior to initiation of study medication.
• • Antiretroviral treatment for 3 weeks prior to initiation of study medication.
• • Systemic steroids or anticancer agents for 4 weeks prior to initiation of study medication.